Carl Ashley Morris - Jan 27, 2023 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role: Chief Scientific Officer
Signature: /s/ by David Tyrone Howton as attorney-in-fact for Carl Ashley Morris
Stock symbol: SLDB
Transactions as of: Jan 27, 2023
Transactions value $: -$3,303
Form type: 4
Date filed: 1/31/2023, 08:18 PM
Previous filing: Jan 5, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLDB	Common Stock	Options Exercise		+1.23K	+6.5%		20.2K	Jan 27, 2023	Direct	F1, F2
transaction	SLDB	Common Stock	Sale	-$3.3K	-441	-2.18%	$7.49	19.8K	Jan 27, 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLDB	Restricted Stock Units	Options Exercise	$0	-1.23K	-24.99%	$0.00	3.7K	Jan 27, 2023	Common Stock	1.23K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Includes 490 shares of common stock and 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively.
F3	This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).
F4	On January 27, 2022 (the "Grant Date"), the reporting person was granted 4,933 restricted stock units, vesting in four equal installments on the anniversary of the grant date.